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ABSTRACT 
Objective: The main aim of the present study was to develop and validate a simple, precise and accurate Reversed-Phase HPLC-PDA method for the 
quantitative determination of Chrysin in solid lipid nanoparticles (SLNs).  
Methods: The RP-HPLC-PDA system equipped with a C-18 reversed-phase column (250 × 4.6 mm, particle size 5 μm) was employed in the present 
study. HPLC grade methanol and water in 85:15 (v/v) ratio was selected as the mobile phase at flow rate of 1 ml/min under an ambient column 
oven temperature. The detection wavelength was kept at 268 nm. Validation of developed method was performed according to the ICH guidelines. 
Results: The developed reversed-phase HPLC-PDA method was found to be linear in the concentration range of 0.2-10 µg/ml with a correlation 
coefficient of 0.999. The method was also observed to be precise with % relative standard deviation (RSD) below 2%. The limit of detection and 
limit of quantification of this method were found to be 0.05µg/ml and 0.14µg/ml, respectively. The percent recovery of the developed method was 
estimated to more than 99%.  
Conclusion: The developed HPLC method can be utilized for the determination of Chrysin with a high degree of accuracy, precision, robustness, 
specificity in solid lipid nanoparticles in the presence of excipients. 
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Chrysin (5, 7-dihydroxyflavone) is a flavonoid and a primary active 
chemical constituent of the Indian trumpet trees (Oroxylum 
indicum). It is also found in chamomile, in the mushroom Pleurotus 
ostreatus, propolis and in honey [1].  
Previous studies also revealed the presence of high Chrysin content 
(approximately 28g/l) in propolis while the Chrysin content in 
honeydew and forest honey was found to be 0.10 mg/kg and 0.53 
mg/kg, respectively [2-3]. Chrysin was reported to have many 
biological activities like anti-oxidant, anti-inflammatory, anti-diabetic, 
anti-cancer, anti-hemolytic, anti-hypertension and neuroprotection [4, 
5]. But the therapeutic potential of Chrysin is severely limited by its 
poor oral bioavailability (F ≤ 0.02%)  which is because of its poor 
aqueous solubility (2-5 μg/ml) and extensive pre-systemic metabolism 
in the intestine and the first-pass metabolism in the liver [6-8]. 
Nanotechnology is widely used as an excellent tool to improve the oral 
bioavailability of flavonoids like quercetin, apigenin, rutin etc. 
Nanoparticles can also influence the pharmacokinetics of drugs which 
affect their bioavailability, metabolism as well as biodistribution 
mainly due to their composition and submicron size [9, 10]. 
Poorly aqueous soluble drugs often exhibit low bioavailability as their 
absorption can be kinetically-limited by low rates of dissolution and 
capacity-limited by poor solubility. Lipid-based formulations can 
reduce the inherent limitations of slow and incomplete dissolution of 
water-insoluble drugs, and facilitate the formation of solubilized 
phases from which absorption may occur [11]. Solid lipid 
nanoparticles (SLNs) have been proposed as an alternative drug 
carrier system to other novel delivery approaches, such as 
microemulsions, microsphere, liposomes and polymeric nanoparticles, 
due to various advantages, including feasibility of incorporation of 
lipophilic and hydrophilic drugs, improve physical stability, low cost, 
ease of scale-up and manufacturing [12] . Nanoemulsions are reported 
to be less physically stable while polymeric nanoparticles are proved 
to be more toxic than SLN [13-16]. Further SLNs are easier to prepare 
and offers more stability than other delivery systems [17].  
Chrysin loaded solid lipid nanoparticles (Ch-SLNs) has been 
developed and evaluated for their physiochemical characterization 
and in vitro anticancer activity against MCF-7 breast cancer cells by 
the authors in their previous work. Chrysin loaded SLNs exhibited 
higher in vitro anticancer activity against the breast cancer cell line 
as compared to that of bulk chrysin [18].  
The literature survey revealed that various analytical methods have 
been depicted for the determination of Chrysin and their derivatives 
in natural products either individually or in the presence of other 
phytochemicals by using HPLC [19, 20]. However, no reports were 
available as yet on reversed-phase HPLC equipped with photodiode 
array detector (RP-HPLCPDA) based methods for the quantification 
of Chrysin in solid lipid nanoparticles. Moreover, none of the 
methods were available for quantification of Chrysin in solid lipid 
nanoparticles where a high specificity is required to surmount the 
likely interference of the excipients. Hence, the objective of the 
present work was to develop an accurate, precise, robust, specific 
and suitable RP-HPLC based method to quantify Chrysin in solid 
lipid nanoparticles to determine entrapment efficiency, total drug 
content with high specificity and prevent interference of excipients. 
The different analytical performance parameters such as linearity, 
precision, accuracy, reproducibility, the limit of detection (LOD) and 
limit of quantification (LOQ) were determined as per ICH Q2 (R1) 
guidelines [19, 21].  
Chrysin (≥98%) and D-α-Tocopherol polyethylene glycol 1000 
succinate (TPGS) was procured from Sigma Aldrich (Mumbai, India) 
while stearic acid and Poloxamer 188 (Lutrol F-68) was purchased 
from Hi-media (Mumbai, India). All HPLC grade solvents and 
chemicals of analytical grade were purchased from Merck Specialties 
(Mumbai, India).  
Modified hot high shear homogenization ultrasonication method was 
used to prepare Chrysin loaded SLNs as reported earlier [18]. Briefly, 
400 mg of solid lipid (stearic acid) was melted and oleic acid (20% of 
stearic acid) was added in the molten lipid and taken as lipid matrix 
for preparation of solid lipid nanoparticles. Co-surfactant like (TPGS) 
was dispersed in the lipid melt and then dissolved in an organic 
solvent (acetone) and then Chrysin was added to the lipid solution. 
Organic solvent was evaporated on a water bath. Further, lipid phase 
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was homogenized in a hot aqueous phase containing 1%w/v 
Poloxamer 188 by utilising high shear homogenizer at 12000 rpm for 
5 min. Resulting dispersion was sonicated using a probe sonicator for 
15 min (3 cycles, 5 min of each) at 40% amplitude and 1 s pulse on-off 
time. Blank SLNs were prepared using the same manner excluding the 
drug. Chrysin loaded solid lipid nanoparticles were successfully 
prepared by using hot high shear homogenization method. The 
particle size, polydispersity index and zeta potential of prepared solid 
lipid nanoparticles was found to be 358±04 nm, 0.268±0.03 and-
51.0±2 mV, respectively. The solid-state characterization and 
morphology studies of prepared Ch-SLNs were carried out along with 
in vitro anticancer activity against MCF-7 cell lines. These results were 
published in the previous work of authors [18]. 
Waters HPLC system consisted of a Waters 515 HPLC binary pumps, 
degasser, Waters 2998 photodiode array (PDA) detector and waters 
column oven. Samples were separated on SunFire C18 column (4.6 
mm x 250 mm, 5 μm) at ambient temperature. All the parameters of 
HPLC were controlled and the results were integrated with 
Empower software. 
HPLC grade methanol and water in the ratio of 85: 15 was used as 
mobile phase. Mobile phase was filtered through 0.22µ PTFE filters 
and degassed by sonicating for 5 min before use. The flow rate and 
injection volume were kept at 1.0 ml/min and 20 μL, respectively. 
The column effluent was monitored at 268 nm by PDA detector. 
Initially, a mobile phase mixture of methanol and water was used to 
develop the HPLC method of Chrysin in SLN. However, the method 
has not proved repeatability or accuracy. Consequently, different 
ratios of methanol and water as mobile phase were used. The best 
peak with respect to width and symmetry was observed with a 
mobile phase of methanol and water in the ratio of 85:15 (v/v) and a 
flow rate of 1.0 ml/min. The peak was detected at 4.6 min (fig. 1) 
and chromatographic conditions were summarized in table 1. 
 
 
Fig. 1: Representative HPLC chromatogram of a 3µg/ml Chrysin standard solution 
 
Table 1: Chromatographic conditions 
Composition Value 
Column SunFire C18 reverse phase column (250 × 4.6 mm, particle size 5 μm) 
Flow rate 1 ml/min 
Retention time 4.57±0.12 min 
Detector PDA detector (Waters 2998) 
Detection wavelength 268 nm 
Injection volume 20 μL 
Temperature Ambient temperature 
Elution type Isocratic 
Run time 14 min 
 
Chrysin standard and Chrysin loaded SLNs equivalent to 10 mg was 
weighed accurately and transferred to 100 ml volumetric flask. A 
small volume of HPLC grade methanol was used to dissolve chrysin 
and further diluted up to mark with the same solvent to get a 
concentration of 100 µg/ml. The solution was filtered through 0.22 
μm syringe filter and further diluted with methanol to yield a 
different concentration.  
The developed HPLC method was validated for linearity, specificity, 
precision, accuracy and robustness as accordance to ICH guidelines 
[21]. Linearity was evaluated in the range of 0.2–10 µg/ml. Different 
concentrations of chrysin were prepared like 0.2, 0.3, 0.5, 0.8, 0.9, 1, 
2, 4, 5, 6, 7 and 10 μg/ml. All the solutions were filtered with 0.22 
µm pore size PVDF Whatman syringe filter prior to injection. Peak 
area versus concentration was subjected to linear regression 
analysis and the slope, intercept and correlation coefficient for the 
calibration was determined. Correlation coefficient is a statistical 
tool used to measure the degree or strength of this type of 
relationship. The linear regression data for the calibration curve 
with equation Y= 136492X+19282 (Where Y is the peak area (mAU) 
and C is the concentration (µg/ml) of the standard solution 
demonstrated a good linear relationship over the concentration 
range of 0.2 to 10 μg/ml. A good linearity was established by a 
correlation coefficient (R2
Limits of detection and quantification were determined from the 
calibration curve using the following equations:  
) value of 0.9992±0.0001. A high 
correlation coefficient value (a value very close to 1.0) indicated a 
high level of linear relationship between the concentration of 







Where σ is the standard deviation of intercepts and S is the slope of 
the calibration curve [23]. 
The LOD and LOQ were found to be 0.05 and 0.14 μg/ml, 
respectively. This indicated that the developed method was more 
sensitive towards analyte as compared to previously reported 
methods [24].  
The specificity of the method was ascertained by analysing the 
standard drug and sample. The peak for Chrysin in SLN samples was 
confirmed by comparing the Retention time (RT) values with that of 
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the standard. The peak purity of Chrysin was assessed by comparing 
the spectra at three different levels, that is, peak start, peak apex, 
and peak end positions of the spectrum. The specificity is considered 
the first analytical validation step, it must be ensured that the 
components of the formulation such as excipients, does not interfere 
in the quantification of the drug. The specificity of the method was 
evaluated by comparing the chromatograms of Chrysin extracted 
from solid lipid nanoparticles with that of standard solution of 
Chrysin. The representative chromatogram of the Chrysin sample 
(fig. 2) showed the peak at approximately 4.6 min, which was in 
agreement with that obtained for the standard (fig. 1). No peaks at 
this retention time were observed in the chromatogram of the blank 
SLNs (fig. 3), which indicated no interference in the quantitative 
determination of Chrysin from the formulation. 
 
 
Fig. 2: Chromatogram of chrysin from solid lipid nanoparticles 
 
 
Fig. 3: Chromatogram of blank SLNs 
 
The method was also validated in terms of repeatability (intra-
day) and intermediate precision (inter-day) as per ICH guidelines 
[21]. Three concentrations of Chrysin (1, 6 and 10 μg/ml) were 
prepared in triplicate and analysed to evaluate the intra-day and 
inter-day precision. The precision results were reported as the 
standard deviation (SD) and the percent relative standard 
deviation (%RSD). The result of repeatability and intermediate 
precision were found within the limit (˂ 2 %RSD). The % RSD of 
intra-day precision and inter-day were found at three different 
concentration (1, 6 and 10µg/ml) less than 2%. These values 
(table 2) were well within the generally acceptable limit of not 
more than 2%. The result confirmed the good precision of the 
developed method of the assay [25]. The responses were 
calculated for each concentration as shown in table 2. 
 
Table 2: Repeatability and intermediate precision of developed HPLC method 
Concentration (μg/ml) Repeatability  Intermediate precision  
Peak area (µv* %RSD sec) Peak area (µv* %RSD sec) 
1 158647.5±389.6 0.24 159412±456 0.28 
6 849458±5566.3 0.66 846701±1667.36 0.19 
10 1403101±12131.8 0.86 1282212±18252.5 1.45 
Data given in mean±SD (n=3) 
 
Accuracy was determined by recovery studies via standard addition 
method. Pre-analysed samples of the formulation of known quantity 
were spiked by 50%, 100% and 150% in standard chrysin solution 
(3μg/ml). Each solution of three different concentrations was 
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prepared in triplicate and suitably diluted and analysed. Recovery 
studies can also be considered as suitable method to determine drug 
content precisely in formulated Chrysin loaded solid lipid 
nanoparticles. The accuracy was assessed by calculating the percent 
recovery and the % RSD of the mean concentration of the analyte. 
The detailed results are presented in table 3. The mean percent 
recovery of Chrysin at three different level (50%, 100% and 150%) 
from the samples were found to be 102.66%, 99.72% and 100.29% 
respectively, which indicated a good agreement between the 
experimental and theoretical values [24]. 
Robustness of the method was evaluated by deliberately introducing 
very small changes in the analytical methodology at a single 
concentration level. Robustness of the proposed method was 
determined in different ways, i.e., by making deliberate changes in 
the mobile phase ratio (±2%), flow rate (±0.1 ml/min.), and 
detection wavelength (±2 nm) of analysis. The percentage of relative 
standard deviation (%RSD) of the experiment was calculated to 
assess the robustness of the method [21]. Factors such as the tailing 
factor, theoretical plates and the capacity factor were taken into 
consideration for testing the system suitability and system 
performance. 
The evaluation of robustness was based on the percent RSD values 
obtained using different parameters for the flow rate of the mobile 
phase. The method was robust concerning these alterations in 
chromatographic parameters (table 4). The retention time was 
found to be deviated less than 5% from the actual value of 4.59 to 
4.68 min. Peak tailing was influenced from 1.34 to 1.47 which 
indicated a good and symmetrical peak. Theoretical plates were also 
found to be more than 9000 above to acceptable limit (˃2000 ). The 
results are presented in table 4. 
  
Table 3: Recovery data for the accuracy of the HPLC method 




Theoretical concentration of 
spiked sample (μg/ml) 
Concentration of spiked 





50 3 4.50 4.61±0.04 102.66±0.92 0.90 
100 3 6 5.98±0.11 99.72±1.84 1.84 
150 3 7.50 7.52±0.13 100.29±1.75 1.75 
Data given in mean±SD (n=3) 
 
Table 4: Robustness data of the HPLC method 
Parameter Study Condition Area (µv* %RSD of area sec) RT (min) % RSD of Rt 
Original Used Level 
Mobile phase ratio (Methanol: Water) 85:15 83:17 -1 1166825±2,650.66 0.23 4.68±0.30 6.42 
85:15 0 
87:13 +1 
Flow rate (ml/min) 1.0 0.9 -1 1278527±1985.78 0.16 4.59±0.34 7.4 
1.0 0 
1.1 +1 
Detection wavelength (nm) 268 266 -1 1318881±843.66 0.06 4.63±0.0 0.0 
268 0 
270 +1 
Data given in mean±SD (n=3) 
 
The HPLC-PDA system with C-18 reversed-phase column (250 × 4.6 
mm, particle size 5 μm) was used in the present method for the 
quantification of Chrysin in solid lipid nanoparticles. Methanol and 
water in ratio of 85:15 (v/v) was selected and detection wavelength 
of 268 nm was used with a flow rate of 1 ml/min. The method was 
validated in terms of linearity, range, accuracy, precision, specificity, 
robustness, detection limit, and quantitation limit according to the 
guidelines of the International Conference on Harmonization (ICH) 
and fulfilled all of the requirements to be considered a reliable 
method. The detection limits and quantification limits were found to 
be 0.05 μg/ml and 0.14 μg/ml, respectively. The developed HPLC 
method can be successfully applied for the quantification of chrysin 
in other formulations including nanoparticles.  
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